Sorry, this entry is only available in Norsk.
Author: Ola Myklebost
Vokste opp på Eiksmarka og Haslum i Bærum, bodde 30 år på Trollåsen i Oppegård, bor nå på Nordnes i Bergen
Publications 2024
[en:]Ranji P, Jonasson E, Andersson L, Filges S, Santamaría ML, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A (2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. J Transl Med DOI: 10.1186/s12967-024-05211-w
Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. e170423. doi: 10.1172/jci.insight.170423
Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024) Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma Nat Commun DOI: 10.1038/s41467-024-47031-y
Andre prosjekter
Publications 2023
[En:]
Anzar, I., B. Malone, P. Samarakoon, I. Vardaxis, B. Simovski, H. Fontenelle, L. A. Meza-Zepeda, R. Stratford, E. Keung, M. Burgess, H. A. Tawbi, O. Myklebost and T. Clancy (2023). “The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.” Front. Immunol. doi: 10.3389/fimmu.2023.1226445
Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science doi: 10.1126/science.abj4784
Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology doi:10.1002/1878-0261.13514 [En:]
Pioneer postdoc announcement
Postdoctoral Research Fellow in pediatric cancer biology
UiB – Knowledge that shapes society
Through robust and close interaction with the world around us – globally, nationally and locally – we shall be instrumental in building a society based on knowledge, skills and attitudes.
Do you want to take part in shaping the future?
Postdoctoral Research Fellow position
Funded by a highly competitive Pioneer Grant for novel and game-changing projects.
At the Faculty of Medicine, Department of Clinical Science, a full-time (100 %) position as Postdoctoral Research Fellow is available for a period of two (2) years. The position is part of the project, ”KidImmune – Autoimmune mechanisms in pediatric cancer”, financed by the Norwegian Cancer Society Pioneer Program. See http://kidimmune.no for more information.
Our small, enthusiastic group consisting of Ola Myklebost, an experienced cell biologist and cancer researcher, and research fellow Anastassia Serguienko, who made the entirely novel discoveries on which this project is built, has the focus completely on this project. Our findings open up a Pandora’s box of fascinating questions that need answers. We have laid a solid foundation of clinical sample collections, proteomic data, technologies, and cell models to give the candidate a flying start.
We have access to expert in-house core facilities for genomics, proteomics, flow cytometry and advanced microscopy.
About the project/work tasks:
- Investigations on how patient autoantibodies may influence important processes in normal and cancer cells in culture
- Using immunohistochemistry, advanced microscopy, flow cytometry, protein chemistry, and various functional assays
Qualifications and personal qualities:
- The applicant must hold a Norwegian PhD or an equivalent degree or have submitted the doctoral thesis prior to the application deadline. It is a condition of employment that the PhD has been awarded at the latest within 31.12.2022
- Work independently and in a structured manner and have good ability to communicate and cooperate.
- Proficiency in both written and oral English is required. Proficiency in Norwegian would be an advantage
- Special requirements for the position: Project experience from mammalian molecular and cell biology is required, including cellular structure and function or advanced human immunology. Competence in excess of course experience in immunology, protein chemistry and function, advanced cell microscopy, or cancer biology would be an advantage
About the position of postdoctoral research fellow:
The position of postdoctoral research fellow is a fixed-term appointment with the primary objective of qualifying the appointee for work in top academic positions. Postdoctoral fellowships are fixed term positions. You can not be employed as a postdoctoral fellow for more than one three-year period at the same institution.
We can offer:
- Exciting development opportunities as part of your role in a strong professional environment
- We have dedicated support for incoming international staff to relocate to Bergen
- Salary level 62 (code 1352/pay framework 24.6) at present NOK 563 900 gross p.a., with a degree in Medicine or Dentistry level 63(code 1352/pay framework 24.7) at present NOK 574 700, with a medical specialization level 65 (code 1352/pay framework 24.9) atpresent NOK 594 300, gross p.a. on the government salary scale. Further promotion will be after service seniority in the position
- Enrolment in the Norwegian Public Service Pension Fund
- Good welfare benefits
- A beautiful location on the coast with easy access to nature, including woods, fjords and high mountains.
Your application must include:
- A brief account of the applicant`s research interests and motivation for applying for the position
- Transcripts and diplomas (applicants with education from other countries than Norway must enclose witnessed diplomas in both the original language and authorized translations) and documentation of submitted doctoral thesis
- Complete list of publications
- Publications (pdf) it is important that each of the scholarly works on which the committee should place special emphasis, is attached in its entirety
- Two referees (name and contact information)
General information:
For further information please contact prof. Ola Myklebost, e-mail: ola.myklebost@uib.no phone: +47 55974573 / +47 90087139
The state labour force shall reflect the diversity of Norwegian society to the greatest extent possible. People with immigrant backgrounds and people with disabilities are encouraged to apply for the position.
The University of Bergen applies the principle of public access to information when recruiting staff for academic positions.
Information about applicants may be made public even if the applicant has asked not to be named on the list of persons who have applied. The applicant must be notified if the request to be omitted is not met.
Further information about our employment process can be found here.
Publications 2022
Namløs H, Skårn M, Ahmed D, Grad I, Andresen K, Kresse S, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind G, Meza-Zepeda LA (2022) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics 23:142. doi: 10.1186/s12864-022-08346-6
Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia 10.1038/s41375-022-01597-y
Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy Genome Med DOI: doi: 10.1186/s13073-022-01090-2
KidImmune, – Autoimmune mechanisms in pediatric cancer
The new project is now our main effort, headed by Anastassia Serguienko, funded by a researcher grant to her from the Pediatric Cancer Association, together with Jeetesh Sharma, who got the postdoc Pioneer grant from the Cancer Society, and from 2024 a project grant from the MOHN Foundation.
Publications 2021
Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021) Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor. Pathology 53:713-719 doi:10.1016/j.pathol.2020.11.010
Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021) Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. PLoS DOI:10.1371/journal.pone.0248140
Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2020) Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer. Int J Cancer Vol.149(11), p.1955-1960 doi: 10.1002/ijc.33749
Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chi-card M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barre-ca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Berard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou E (2021) Accurate detection and classification of Ewing sarcoma tumors based on cell-free DNA fragmentation patterns inferred from whole genome sequencing. Nature Communications 28;12(1):3230. doi: 10.1038/s41467-021-23445-w
Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021) Methylation-dependent SUMOylation of the architectural transcription factor HMGA2. Biochemical and Biophysical Research Communications, doi: 10.1016/j.bbrc.2021.02.099
Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021) The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine 13:142. doi: 10.1186/s13073-021-00955-2